Terms: = Lung cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Treatment
85 results:
1. Development and validation of a nomogram to predict leptomeningeal metastases in lung adenocarcinoma: Cervical lymph node metastasis is an important association factor.
Hua X; Feng W; Ye M; Lai M; Yu X; Sun M; Li J; Ai R; He Y; Cai L; Shi C; Liu X
Cancer Med; 2024 May; 13(9):e7206. PubMed ID: 38686619
[TBL] [Abstract] [Full Text] [Related]
2. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer.
Struebing A; McKibbon C; Ruan H; Mackay E; Dennis N; Velummailum R; He P; Tanaka Y; Xiong Y; Springford A; Rosenlund M
J Comp Eff Res; 2024 May; 13(5):e230175. PubMed ID: 38573331
[No Abstract] [Full Text] [Related]
3. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
[TBL] [Abstract] [Full Text] [Related]
4. Multi-institutional study of 'Sandwich treatment' for motor area large brain metastases (LBM) with diameter over 3 cm.
Wang Z; Chen H; Chen Q; Zhu Y; Li M; Zhou J
Radiol Oncol; 2024 Mar; 58(1):145-152. PubMed ID: 38183280
[TBL] [Abstract] [Full Text] [Related]
5. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
[TBL] [Abstract] [Full Text] [Related]
6. Yttrium-90 Transarterial Radioembolization of Primary lung cancer Metastases to the Liver.
Alexander ES; Petre EN; Zhao K; Sotirchos V; Namakydoust A; Moussa A; Yuan G; Sofocleous CT; Solomon SB; Ziv E
J Vasc Interv Radiol; 2024 Feb; 35(2):214-225.e2. PubMed ID: 37923172
[TBL] [Abstract] [Full Text] [Related]
7. Sublobar resection versus lobectomy for stage IA non-small-cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.
Meldola PF; Toth OAS; Schnorrenberger E; Machado PG; Chiarelli GFC; Kracik JLS; de Carvalho CC; Lôbo MM; Gross JL
Surg Oncol; 2023 Dec; 51():101995. PubMed ID: 37776757
[TBL] [Abstract] [Full Text] [Related]
8. Exposure to Agent Orange is associated with increased recurrence after surgical treatment of stage I non-small cell lung cancer.
Subramanian MP; Eaton DB; Labilles UL; Heiden BT; Chang SH; Yan Y; Schoen MW; Patel MR; Kreisel D; Nava RG; Thomas TS; Meyers BF; Kozower BD; Puri V
J Thorac Cardiovasc Surg; 2024 May; 167(5):1591-1600.e2. PubMed ID: 37709166
[TBL] [Abstract] [Full Text] [Related]
9. CT-based non-invasive identification of the most common gene mutation status in patients with non-small cell lung cancer.
Chen Z; Gao S; Ding C; Luo T; Xu J; Xu S; Li S
Med Phys; 2024 Mar; 51(3):1872-1882. PubMed ID: 37706584
[TBL] [Abstract] [Full Text] [Related]
10. cancer survival analysis and spatial distribution during 2014-2016 in Shandong Province, China.
Jiang F; Fu Z; Lu Z; Chu J; Xu A; Guo X; Ma J
Sci Rep; 2023 Jun; 13(1):10324. PubMed ID: 37365230
[TBL] [Abstract] [Full Text] [Related]
11. Risk profiles and a concise prediction model for lymph node metastasis in patients with lung adenocarcinoma.
Liang S; Huang YY; Liu X; Wu LL; Hu Y; Ma G
J Cardiothorac Surg; 2023 Jun; 18(1):195. PubMed ID: 37340322
[TBL] [Abstract] [Full Text] [Related]
12. Chemoimmunotherapy vs. Immunotherapy for First Line treatment of Advanced Non-small Cell lung cancer With a PD-L1 Expression ≥50% or ≥90.
Shah M; Mamtani R; Marmarelis ME; Hennessy S
Clin Lung Cancer; 2023 May; 24(3):235-243. PubMed ID: 36935244
[TBL] [Abstract] [Full Text] [Related]
13. Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis.
Taioli E; Wolf A; Alpert N; Rosenthal D; Flores R
J Surg Oncol; 2023 Jul; 128(1):134-141. PubMed ID: 36932968
[TBL] [Abstract] [Full Text] [Related]
14. Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort.
Bringuier M; Carton M; Debieuvre D; Pasquier D; Perol M; Filleron T; Léna H; Quantin X; Simon G; Baldini C
J Geriatr Oncol; 2023 Mar; 14(2):101423. PubMed ID: 36657245
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of Carboplatin With Cisplatin in Small Cell lung cancer in US Veterans.
Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
[TBL] [Abstract] [Full Text] [Related]
16. Follow-up strategy and survival for five common cancers: A meta-analysis.
Galjart B; Höppener DJ; Aerts JGJV; Bangma CH; Verhoef C; Grünhagen DJ
Eur J Cancer; 2022 Oct; 174():185-199. PubMed ID: 36037595
[TBL] [Abstract] [Full Text] [Related]
17. Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.
Groarke EM; Patel BA; Shalhoub R; Gutierrez-Rodrigues F; Desai P; Leuva H; Zaimoku Y; Paton C; Spitofsky N; Lotter J; Rios O; Childs RW; Young DJ; Dulau-Florea A; Dunbar CE; Calvo KR; Wu CO; Young NS
Leukemia; 2022 Sep; 36(9):2328-2337. PubMed ID: 35896822
[TBL] [Abstract] [Full Text] [Related]
18. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell lung cancer: A Retrospective Multicohort Study.
Tong H; Sun J; Fang J; Zhang M; Liu H; Xia R; Zhou W; Liu K; Chen X
Front Immunol; 2022; 13():859323. PubMed ID: 35572597
[TBL] [Abstract] [Full Text] [Related]
19. A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment.
Jiang Y; Wang Y; Fu S; Chen T; Zhou Y; Zhang X; Chen C; He LN; Du W; Li H; Lin Z; Zhao Y; Yang Y; Zhao H; Fang W; Huang Y; Hong S; Zhang L
Thorac Cancer; 2022 Jun; 13(11):1558-1569. PubMed ID: 35437945
[TBL] [Abstract] [Full Text] [Related]
20. A Combination of Radiomic Features, Imaging Characteristics, and Serum Tumor Biomarkers to Predict the Possibility of the High-Grade Subtypes of lung Adenocarcinoma.
Liu Y; Chang Y; Zha X; Bao J; Wu Q; Dai H; Hu C
Acad Radiol; 2022 Dec; 29(12):1792-1801. PubMed ID: 35351366
[TBL] [Abstract] [Full Text] [Related]
[Next]
